Optimal Medical Therapy for Secondary Prevention of Acute Coronary Syndrome: A Retrospective Study from a Tertiary Hospital in Sudan

被引:2
作者
Ahmed, Kannan O. [1 ]
Ahmed, Ashraf M. [1 ]
Wali, Mojahed B. [1 ]
Ali, Ali H. [1 ]
Azhari, Mustafa M. [1 ]
Babiker, Anas [2 ]
Yousef, Bashir A. [3 ]
Muddather, Hiba F. [1 ]
机构
[1] Univ Gezira, Fac Pharm, Dept Clin Pharm & Pharm Practice, Wad Madani, Sudan
[2] Royal Care Int Hosp, Dept Cardiol, Khartoum, Sudan
[3] Univ Khartoum, Fac Pharm, Dept Pharmacol, Khartoum, Sudan
关键词
acute coronary syndrome; discharge; optimal medical therapy; secondary prevention; Sudan; INTERVENTION; GUIDELINES;
D O I
10.2147/TCRM.S361129
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background: Five-medication regimen is recommended for patients after acute coronary syndrome (ACS) as a secondary prevention strategy at discharge to reduce recurrence and improve mortality. Objective: This study aimed to assess prescribing of optimal medical therapy (OMT) as five-medication regimens for secondary prevention at discharge after ACS in Sudan. Methods: A retrospective cohort study was performed at a tertiary hospital located in Wad Medani, Sudan, in the period between January and December 2019. Data were collected from patients' files. OMT was defined as a combination of five medications; aspirin and P2Y12 inhibitors, statins, beta-blockers (BBs), and angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin receptor blockers (ARBs) or if a valid contraindication was documented. Results: Of the 619 patients throughout the study period, 591 were selected based on inclusion and exclusion criteria. The median age of patients was 60 years, and 58.9% of patients were male. Diabetes (44.5%) and hypertension (42%) were the most common risk factors. Most patients (58.4%) were diagnosed with ST-segment elevation myocardial infarction. About 99.7% of patients were on aspirin, 99.5% on statins, 97% on clopidogrel, 96.8% on dual antiplatelet therapy, 70.4% on BBs, and 57.9% on ACEIs/ARBs. OMT for secondary prevention was prescribed to 267 (45.2%) patients with ACS at discharge. Conclusion: Although prescriptions for all five guideline-recommended medications after ACS were suboptimal, the study showed a positive trend in prescribing most individual medications.
引用
收藏
页码:391 / 398
页数:8
相关论文
共 29 条
[1]   Comparison of Effects of ACEIs and ARBs on Albuminuria and Hyperkalemia in Indonesian Hypertensive Type 2 Diabetes Mellitus Patients [J].
Agustina, Putri S. ;
Yunir, Em ;
Prawiroharjo, Pukovisa ;
Damanik, Johanda ;
Sauriasari, Rani .
INTERNATIONAL JOURNAL OF HYPERTENSION, 2020, 2020
[2]   Clinical Pharmacist's Intervention to Improve Medication Titration for Heart Failure: First Experience from Sudan [J].
Ahmed, Kannan O. ;
Eldin, Imad Taj ;
Yousif, Mirghani ;
Albarraq, Ahmed A. ;
Yousef, Bashir A. ;
Ahmed, Nasrein ;
Babiker, Anas .
INTEGRATED PHARMACY RESEARCH AND PRACTICE, 2021, 10 :135-143
[3]   Impact of clinical pharmacist intervention in anticoagulation clinic in Sudan [J].
Ahmed, Nahid Osman ;
Osman, Bashier ;
Abdelhai, Yassein Mohamed ;
El-Hadiyah, Tariq Muhammed Hashim .
INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2017, 39 (04) :769-773
[4]   Impact of evidence-based cardiac medication on short- and long-term mortality in 7,567 acute coronary syndrome patients in the Gulf RACE-II registry [J].
Al-Zakwani, Ibrahim ;
Sulaiman, Kadhim ;
Al Za'abi, Mohammed ;
Panduranga, Prashanth ;
Al-Habib, Khalid ;
Asaad, Nidal ;
Al Motarreb, Ahmed ;
Hersi, Ahmad ;
Al Faleh, Husam ;
Al Saif, Shukri ;
Almahmeed, Wael ;
Amin, Haitham ;
Alsheikh-Ali, Alawi ;
Al Lawati, Jawad ;
Al Suwaidi, Jassim .
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2012, 50 (06) :418-425
[5]  
[Anonymous], 2021, Eur Heart J, V42, P1908, DOI 10.1093/eurheartj/ehaa895
[6]   Beyond Medication Prescription as Performance Measures [J].
Arnold, Suzanne V. ;
Spertus, John A. ;
Masoudi, Frederick A. ;
Daugherty, Stacie L. ;
Maddox, Thomas M. ;
Li, Yan ;
Dodson, John A. ;
Chan, Paul S. .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2013, 62 (19) :1791-1801
[7]   Optimal medical therapy for secondary prevention after an acute coronary syndrome: 18-month follow-up results at a tertiary teaching hospital in South Korea [J].
Byeon, Hee Ja ;
Yang, Young-Mo ;
Choi, Eun Joo .
THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2016, 12 :167-175
[8]   Secondary prevention therapies in acute coronary syndrome and relation to outcomes: observational study [J].
Chow, Clara K. ;
Brieger, David ;
Ryan, Mark ;
Kangaharan, Nadarajah ;
Hyun, Karice K. ;
Briffa, Tom ;
Xu, Kitty ;
Kilian, Jens ;
Myers, Jo-dee ;
Parkin, Ray ;
Morrison, Anne ;
Rajaratnam, Rohan ;
Tattam, Erin ;
Waites, Jonathon ;
Baldo, Clara ;
Kamaladasa, Kanishka ;
Davies, Maria ;
Collins, Nicholas ;
Nyman, Elizabeth ;
Blenkhorn, Adam ;
Boys, Janice ;
Juergens, Craig ;
Plotz, Elza ;
Fitzpatrick, Drew ;
Barry, Lisa ;
Amos, David ;
Ryan, Estelle ;
Adams, Mark ;
Watson, Danica ;
Alford, Kevin ;
Turnbull, Rhonda ;
Robinson, Karley ;
Weaver, James ;
Shrestha, Prakriti ;
Chow, Clara ;
Tsang, Tracy ;
Shetty, Pratap Chandra ;
Stubbs, Renee ;
Farshid, Ahmad ;
Taverner, Pearle ;
Corkill, Wendy ;
Ilton, Marcus ;
Matthews, Krystal ;
Coverdale, Steve ;
Johnston, Colleen ;
Walters, Darren ;
Stibijl, Kathryn ;
Jayasinghe, Rohan ;
Gunter, Helen ;
Atherton, John .
HEART ASIA, 2019, 11 (01)
[9]   Meta-analysis: Secondary prevention programs for patients with coronary artery disease [J].
Clark, AM ;
Harding, L ;
Vandermeer, B ;
McAlister, FA .
ANNALS OF INTERNAL MEDICINE, 2005, 143 (09) :659-672
[10]  
Elhasan OBM., 2014, Sudan JMS, V1, P111